PD-1/PD-L1抑制剂在晚期肝细胞肝癌治疗中的研究进展  

Research progress in the use of PD-1/PD-L1 inhibitors for advanced hepatocellular carcinoma

作　　者：李洁琅 陈婷[1] 杨雨[1] Jielang Li;Ting Chen;Yu Yang(Department of Abdominal Oncology,West China Hospital,Sichuan University,Chengdu 610000,China)

机构地区：[1]四川大学华西医院腹部肿瘤科,成都市610000

出　　处：《中国肿瘤临床》2020年第5期265-268,共4页Chinese Journal of Clinical Oncology

摘　　要：晚期原发性肝细胞肝癌(hepatocellular carcinoma,HCC)的系统治疗主要包括靶向治疗、化疗以及免疫治疗。近3年,程序性死亡受体-1(programmed death receptor-1,PD-1)/程序性死亡受体-1配体(programmed death receptor-1 ligand,PD-L1)抑制剂在晚期HCC治疗中取得突破性进展。纳武单抗(nivolumab)和帕博利珠单抗(pembrolizumab)先后被美国食品药品管理局(FDA)批准用于HCC二线治疗。多个PD-1/PD-L1抑制剂联合系统治疗的Ⅰ、Ⅱ期临床研究初步显示出较好的疗效和安全性。阿特珠单抗(atezolizumab)联合贝伐单抗一线治疗成为首个在Ⅲ期临床研究中证实优于现有标准治疗索拉非尼的全新疗法。本文就近年PD-1/PD-L1抑制剂在晚期HCC治疗中的研究进展进行概述。Systemic treatment of advanced hepatocellular carcinoma(HCC) includes targeted therapy, chemotherapy, and immunotherapy. In recent years, the treatment of advanced HCC has progressed with the use of programmed death receptor-1(PD-1)/programmed death receptor-1 ligand(PD-L1) inhibitors. Nivolumab and pembrolizumab have been approved by the US Food and Drug Administration(FDA) as a second-line treatment for advanced HCC. Multiple phase I/II clinical studies of PD-1/PD-L1 inhibitors combined with other systemic treatments have revealed good efficacy and safety. In a phase III clinical study, atezolizumab plus bevacizumab, as a new first-line treatment strategy, has been shown to be superior to the existing standard treatment(sorafenib). Here, we review the current research and progress in the use of PD-1/PD-L1 inhibitors for advanced HCC.

关 键 词：肝细胞癌 免疫治疗 PD-1抑制剂 PD-L1抑制剂 

分 类 号：R735.7[医药卫生—肿瘤]